DNA repair and survival in lung cancer - The two faces of janus

New England Journal of Medicine

Volumn 356, Issue 8, 2007, Pages 771-773

  Gazdar, Adi F ^a,b  

^a Hamon Center for Therapeutic Oncology Research   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; GEMCITABINE; OXALIPLATIN; PLATINUM;

AGING; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; CYTOTOXICITY; DNA REPAIR; DNA REPLICATION; DNA SEQUENCE; DRUG DNA BINDING; EXCISION REPAIR; GENE MUTATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; SURVIVAL TIME; TESTIS TUMOR;

EID: 33847127528     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp068308     Document Type: Article

References (5)

1. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001;1:22-33.
2. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91.
3. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006;17:1818-25.
4. Reed E. ERCC1 measurements in clinical oncology. N Engl J Med 2006;355:1054-5.
5. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80.